A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-02-26
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-20 (study day 133); relationship: not assessed
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 350); relationship: N
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-04 (study day 360); relationship: N
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-16 (study day 433); relationship: Y
Data queries
No data queries.